Back to announcement
20260923_PRDL_Laporan Penggunaan Dana Hasil Penawaran Umum_32150564_lamp1.pdf
Other Text extracted PRDLSource file signed link, expires in 15 minutes
Extracted text 12
Page 1
Page 2
Page 3
Page 4
Page 5
KETERBUKAAN INFORMASI KEPADA PEMEGANG SAHAM
PT PRODIA DIAGNOSTIC LINE TBK
(“KETERBUKAAN INFORMASI”)
KETERBUKAAN INFORMASI INI DITERBITKAN SEHUBUNGAN DENGAN RENCANA PERUBAHAN
PENGGUNAAN DANA HASIL PENAWARAN UMUM PERDANA SAHAM (IPO) PT PRODIA
DIAGNOSTIC LINE TBK.
INFORMASI SEBAGAIMANA TERCANTUM DALAM KETERBUKAAN INFORMASI INI
DISAMPAIKAN OLEH PERSEROAN DALAM RANGKA MEMENUHI KETENTUAN PERATURAN
OTORITAS JASA KEUANGAN (POJK) POJK NO. 40 TAHUN 2025 TENTANG LAPORAN REALISASI
PENGGUNAAN DANA HASIL PENAWARAN UMUM; SERTA POJK NO. 31/POJK.04/2015
TENTANG KETERBUKAAN ATAS INFORMASI ATAU FAKTA MATERIAL OLEH EMITEN ATAU
PERUSAHAAN PUBLIK.
Informasi sebagaimana tercantum dalam Keterbukaan Informasi ini penting untuk dibaca dan diperhatikan oleh
pemegang saham Perseroan. Jika Anda mengalami kesulitan untuk memahami informasi sebagaimana tercantum
dalam Keterbukaan Informasi ini, sebaiknya Anda berkonsultasi dengan penasehat hukum, akuntan publik,
penasihat keuangan, atau profesional lainnya.
PT Prodia Diagnostic Line Tbk
(“Perseroan”)
Kegiatan Usaha:
Bergerak dalam Bidang Pembuatan dan Pengolahan Alat Kesehatan Terkait Diagnosa Medis
Kantor Pusat:
PT Prodia Diagnostic Line Tbk
Kawasan Industri Jababeka III, Jl. Tekno Boulevard Blok A3 Unit 3A-5-6, Jawa Barat 17530, Indonesia
Telepon: (021) 21-8984 2722
Email: corporate.secretary@proline.co.id
Situs Web: www.proline.co.id
Keterbukaan Informasi ini diterbitkan di Cikarang pada tanggal 17 September 2026
Page 6
I. PENDAHULUAN
PT Prodia Diagnostic Line Tbk (“Perseroan”) dengan ini menyampaikan keterbukaan informasi kepada publik
sehubungan dengan rencana perubahan penggunaan dana hasil Penawaran Umum Perdana Saham (Initial Public
Offering/IPO).
Berdasarkan Keputusan Direksi Perseroan Nomor 007/SK/PROLINE/IX/2026 tanggal 15 September 2026 (“Keputusan
Direksi”), Direksi Perseroan telah menyetujui perubahan rencana penggunaan sebagian Dana Bersih IPO berupa
pengalihan alokasi dari Modal Kerja (Working Capital) menjadi Belanja Modal (Capital Expenditure).
Penyampaian keterbukaan informasi ini dilakukan dalam rangka memenuhi ketentuan peraturan perundang-undangan
yang berlaku, antara lain:
● Peraturan Otoritas Jasa Keuangan Nomor 40 Tahun 2025 tentang Penggunaan Dana Hasil Penawaran Umum
(“POJK 40/2025”) dan
● Peraturan Nomor I-E tentang Kewajiban Penyampaian Informasi, Lampiran Keputusan Direksi PT Bursa Efek
Indonesia Nomor Kep-00087/BEI/12-2025 (“Peraturan I-E”).
II. URAIAN PERUBAHAN PENGGUNAAN DANA
Total dana hasil IPO Perseroan (dana bersih setelah dikurangi biaya emisi efek) adalah sebesar Rp57.696.242.360.
Perseroan berencana melakukan penyesuaian penggunaan dana dengan rincian sebagai berikut:
Sebelum Sesudah Perbedaan
Penggunaan Dana IPO
Rp % Rp % Rp %
Pelunasan Pokok Fasilitas Kredit
35.666.666.667 61,64% 35.666.666.667 61,64% - 0,00%
(BCA & Panin)
Belanja Modal (Capital
16.304.707.087 28,18% 16.304.707.087 28,18% - 0,00%
Expenditure)
Modal Kerja (Working Capital) 5.724.868.606 10,18% 5.724.868.606 10,18% - 0,00%
Total 57.696.242.360 100,00% 57.696.242.360 100,00% - 0,00%
Perubahan alokasi Belanja Modal (Capital Expenditure) sebesar kurang lebih Rp2.500.000.000 atau sekitar 3,98% dari
total dana IPO untuk pengadaan Air Handling Unit (AHU) pada ruang produksi kering (dry production room) berasal
dari alokasi pengadaan mesin produksi Hematologi (Automatic System by Robotic and Manual Pallet Dispensing).
Perubahan alokasi dilakukan karena tingkat utilisasi fasilitas produksi Hematologi saat ini masih relatif rendah, sekitar
0,3%, sehingga kebutuhan terhadap automatic system tersebut belum menjadi prioritas dalam kondisi operasional
saat ini. Dengan kapasitas yang masih tersedia, kebutuhan produksi Hematologi masih dapat dipenuhi menggunakan
fasilitas yang ada tanpa penambahan sistem otomatis tersebut dalam waktu dekat.
Perubahan ini bersifat terbatas dan ditetapkan dengan mempertimbangkan kapasitas terpakai dan kondisi usaha
Perseroan serta prinsip kehati-hatian, dengan tetap mengacu pada ketentuan yang berlaku.
III. PERTIMBANGAN DAN ALASAN PERUBAHAN
Perubahan penggunaan dana ini dilakukan dengan mempertimbangkan kondisi usaha Perseroan, antara lain sebagai
berikut:
1. Kebutuhan Pengendalian Suhu dan Kelembaban pada Ruang Produksi Kering
Page 7
Ruang produksi kering Perseroan digunakan untuk menangani bahan baku yang memerlukan pengendalian suhu dan
kelembaban secara terjaga guna mempertahankan stabilitas material, serta menjaga konsistensi mutu produk sesuai
dengan standar produksi dan sistem manajemen mutu yang berlaku. Berdasarkan evaluasi kebutuhan operasional
yang dilakukan secara berkelanjutan, Perseroan mengidentifikasi kebutuhan penambahan Air Handling Unit (“AHU”)
pada ruang produksi kering setelah penyusunan Prospektus.
2. Penyesuaian Kapasitas Sistem Tata Udara terhadap Rencana Pengembangan Produk Baru
Sejalan dengan rencana produk baru yang membutuhkan lingkungan produksi tertentu, Perseroan memandang perlu
untuk menambah sistem tata udara ruang produksi kering. Penambahan AHU tersebut ditujukan untuk memastikan
kondisi lingkungan produksi tetap terjaga secara optimal seiring dengan peningkatan aktivitas operasional, sehingga
kualitas dan konsistensi proses produksi dapat tetap dipertahankan.
IV. DASAR DAN PROSEDUR PERUBAHAN PENGGUNAAN DANA
Perseroan menegaskan bahwa:
● Nilai perubahan bersifat terbatas (sekitar 3,98% dari total dana bersih IPO, di bawah 20%);
● Perubahan ini dilakukan dengan memperhatikan ketentuan yang berlaku, termasuk Anggaran Dasar
Perseroan dan dokumen penawaran umum;
● Perubahan ini akan dilaporkan dalam Laporan Realisasi Penggunaan Dana secara berkala kepada Otoritas
Jasa Keuangan dan Bursa Efek Indonesia;
● Tidak terdapat dampak material terhadap kegiatan usaha dan kelangsungan usaha Perseroan.
V. IMPLIKASI TERHADAP PERSEROAN
Sehubungan dengan Rencana Perubahan Penggunaan Dana IPO, maka implikasinya pada Laporan Keuangan Perseroan
adalah sebagai berikut:
● Posisi Aset Lancar sesudah Rencana Perubahan Penggunaan Dana IPO menjadi lebih kecil sebesar kurang
lebih Rp2.500.000.000,- dibandingkan sebelum Rencana Perubahan Penggunaan Dana IPO (dana yang semula
direncanakan sebagai modal kerja/aset lancar dialihkan menjadi belanja modal/aset tidak lancar);
● Posisi Aset Tidak Lancar sesudah Rencana Perubahan Penggunaan Dana IPO menjadi lebih besar sebesar
kurang lebih Rp2.500.000.000,- dibandingkan sebelum Rencana Perubahan Penggunaan Dana IPO;
● Posisi Total Aset, Total Liabilitas dan Total Ekuitas tidak mengalami perubahan antara sebelum dan sesudah
Rencana Perubahan Penggunaan Dana IPO.
Simulasi Implikasi Keuangan atas Perubahan Penggunaan Dana IPO
Saldo Saat Ini Simulasi Saldo Setelah Penggunaan Dana IPO
(dalam ribuan) (dalam ribuan)
Sebelum Sesudah
30 Juni 2026 Perbedaan
Perubahan Perubahan
Aset Lancar Rp40.343.975 Rp117.402.176 Rp117.402.176 [Rp / -]
Aset Tidak
Rp145.904.104 Rp162.208.811 Rp162.208.811 [Rp / -]
Lancar
Total Aset Rp186.248.080 Rp279.610.987 Rp279.610.987 [Rp / -]
Total Liabilitas Rp112.027.143 Rp147.693.809 Rp147.693.809 [Rp / -]
Total Ekuitas Rp74.220.936 Rp131.917.178 Rp131.917.178 [Rp / -]
Page 8
Adapun dampak kejadian Informasi tersebut terhadap kegiatan operasional, hukum, kondisi keuangan, atau
kelangsungan usaha Perseroan adalah sebagai berikut:
Rencana perubahan penggunaan Dana Hasil Penawaran Umum (IPO) tidak memberikan dampak material terhadap
kegiatan operasional, aspek hukum, kondisi keuangan, maupun kelangsungan usaha Perseroan.
VI. PERNYATAAN DIREKSI
Direksi Perseroan menyatakan bahwa seluruh informasi dalam Keterbukaan Informasi ini telah disampaikan secara
lengkap, benar, dan tidak menyesatkan, serta tidak terdapat informasi penting lain yang tidak diungkapkan yang dapat
menyebabkan informasi dalam Keterbukaan Informasi ini menjadi tidak benar atau menyesatkan.
VII. PENUTUP
Perseroan berkomitmen untuk senantiasa mematuhi ketentuan peraturan perundang-undangan di bidang pasar
modal dan menerapkan prinsip keterbukaan informasi kepada masyarakat. Perubahan penggunaan dana ini
diharapkan dapat mendukung kebutuhan operasional, menjaga mutu proses produksi, dan memberikan manfaat
yang berkelanjutan bagi Perseroan dan para pemegang saham.
VIII. TAMBAHAN INFORMASI
Bagi pemegang saham yang memerlukan informasi tambahan sehubungan dengan peristiwa ini, dapat menghubungi
Perseroan pada setiap hari kerja dan jam kerja Perseroan pada alamat sebagaimana tersebut di bawah ini:
PT Prodia Diagnostic Line Tbk
Kawasan Industri Jababeka III, Jl. Tekno Boulevard Blok A3 Unit 3A-5-6, Jawa Barat 17530, Indonesia
Telepon: (021) 21-8984 2722
Email: corporate.secretary@proline.co.id
Situs Web: www.proline.co.id
Cikarang, 17 September 2026
Direksi Perseroan
Page 9
INFORMATION DISCLOSURE TO THE SHAREHOLDERS OF
PT PRODIA DIAGNOSTIC LINE TBK
(“INFORMATION DISCLOSURE”)
THIS INFORMATION DISCLOSURE IS ISSUED IN CONNECTION WITH THE PLAN TO CHANGE THE
USE OF PROCEEDS FROM THE INITIAL PUBLIC OFFERING (IPO) OF SHARES OF PT PRODIA
DIAGNOSTIC LINE TBK.
THE INFORMATION AS SET OUT IN THIS DISCLOSURE IS PROVIDED BY THE COMPANY IN
ORDER TO COMPLY WITH THE PROVISIONS OF FINANCIAL SERVICES AUTHORITY (POJK)
REGULATION NO. 40 OF 2025 CONCERNING REPORTS ON THE REALIZATION OF THE USE OF
PROCEEDS FROM PUBLIC OFFERINGS; AS WELL AS POJK REGULATION NO. 31/POJK.04/2015
CONCERNING DISCLOSURE OF INFORMATION OR MATERIAL FACTS BY ISSUERS OR PUBLIC
COMPANIES.
The information set out in this Information Disclosure is important and should be read carefully by the Company’s
shareholders. If you have difficulties understanding the information contained in this Information Disclosure, you
should consult a legal advisor, public accountant, financial advisor, or other professional.
PT Prodia Diagnostic Line Tbk
(“Company”)
Business Activities:
Engaged in the Manufacturing and Processing of Medical Devices Related to Medical Diagnostics
Head Office:
PT Prodia Diagnostic Line Tbk
Kawasan Industri Jababeka III, Jl. Tekno Boulevard Blok A3 Unit 3A-5-6, West Java 17530, Indonesia
Phone: (021) 21-8984 2722
Email: corporate.secretary@proline.co.id
Website: www.proline.co.id
This Information Disclosure is issued in Cikarang on September 17, 2026
Page 10
I. INTRODUCTION
PT Prodia Diagnostic Line Tbk (the “Company”) hereby submits this information disclosure to the public in connection
with the plan to change the use of proceeds from the Initial Public Offering (IPO).
Pursuant to the Company’s Board of Directors’ Decision No. 007/SK/PROLINE/IX/2026 dated 15 September 2026 (the
“Board of Directors’ Decision”), the Company’s Board of Directors has approved the change in the plan for the use of a
portion of the IPO Net Proceeds, in the form of a reallocation from Working Capital to Capital Expenditure.
The submission of this information disclosure is made in order to comply with the applicable laws and regulations,
including but not limited to:
● Financial Services Authority Regulation No. 40 of 2025 concerning the Use of Proceeds from Public Offerings
(“POJK 40/2025”); and
● Regulation No. I-E concerning the Obligation to Submit Information, an Attachment to the Decision of the
Board of Directors of PT Bursa Efek Indonesia No. Kep-00087/BEI/12-2025 (“Regulation I-E”).
II. DESCRIPTION OF THE CHANGE IN USE OF PROCEEDS
The total proceeds from the Company’s IPO (net proceeds after deducting share issuance costs) amounted to
Rp57,696,242,360. The Company plans to adjust the use of proceeds with the following details:
Before After Variance
Use of IPO Proceeds
Rp % Rp % Rp %
Repayment of Bank Credit
35,666,666,667 61.64% 35,666,666,667 61.64% - 0.00%
Facility Principal (BCA & Panin)
Capital Expenditure 16,304,707,087 28.18% 16,304,707,087 28.18% - 0.00%
Working Capital 5,724,868,606 10.18% 5,724,868,606 10.18% - 0.00%
Total 57,696,242,360 100.00% 57,696,242,360 100.00% - 0.00%
The change in allocation to Capital Expenditure of approximately Rp2,500,000,000, or approximately 3.98% of total
IPO proceeds, for the procurement of an Air Handling Unit (AHU) for the dry production room, is sourced from the
allocation originally intended for the procurement of Hematology production machinery (Automatic System by
Robotic and Manual Pallet Dispensing).
The reallocation was made because the current utilization rate of the Hematology production facility remains
relatively low, at approximately 0.3%, such that the need for the automatic system is not yet a priority under current
operating conditions. Given the capacity that remains available, Hematology production needs can still be met using
existing facilities without the addition of such an automatic system in the near term.
This change is limited in nature and has been determined by taking into account current capacity utilization and the
Company’s business conditions, as well as the principle of prudence, while remaining in compliance with applicable
regulations.
III. CONSIDERATIONS AND REASONS FOR THE CHANGE
The change in the use of proceeds is made by taking into account the Company’s business conditions, among others, as
follows:
1. Need for Temperature and Humidity Control in the Dry Production Room
Page 11
The Company’s dry production room is used to handle raw materials that require controlled temperature and
humidity conditions in order to maintain material stability, as well as to ensure consistent product quality in
accordance with applicable production standards and quality management systems. Based on an ongoing evaluation
of operational needs, the Company identified the need for an additional Air Handling Unit (“AHU”) in the dry
production room after the Prospectus had been prepared.
2. Adjustment of Air Handling System Capacity to Support the New Product Development Plan
In line with the plan for new products that require specific production environments, the Company considers it
necessary to add to the air handling system in the dry production room. The additional AHU is intended to ensure that
production environment conditions remain properly maintained as operational activities increase, thereby preserving
the quality and consistency of the production process.
IV. BASIS AND PROCEDURE FOR THE CHANGE IN USE OF PROCEEDS
The Company affirms that:
● The value of the change is limited in nature (approximately 3.98% of total IPO net proceeds, below 20%);
● This change has been carried out with due regard to applicable regulations, including the Company’s Articles
of Association and the public offering documents;
● This change will be reported periodically in the Report on the Realization of the Use of Proceeds to the
Financial Services Authority and the Indonesia Stock Exchange;
● There is no material impact on the Company’s business activities and business continuity.
V. IMPLICATIONS FOR THE COMPANY
In connection with the Plan to Change the Use of IPO Proceeds, the implications on the Company’s Financial
Statements are as follows:
● The position of Current Assets after the Plan to Change the Use of IPO Proceeds decreases by approximately
Rp2,500,000,000 compared to before the change (funds originally planned as working capital/current assets
are reallocated to capital expenditure/non-current assets);
● The position of Non-Current Assets after the Plan to Change the Use of IPO Proceeds increases by
approximately Rp2,500,000,000 compared to before the change;
● The positions of Total Assets, Total Liabilities, and Total Equity remain unchanged before and after the Plan to
Change the Use of IPO Proceeds.
Simulation of Financial Implications from the Change in the Use of IPO Proceeds
Current Balance Simulated Balance After Use of IPO Proceeds
(in thousands) (in thousands)
30 June 2026 Before Change After Change Variance
Current Assets Rp40,343,975 Rp117,402,176 Rp117,402,176 [Rp / -]
Non-Current
Rp145,904,104 Rp162,208,811 Rp162,208,811 [Rp / -]
Assets
Total Assets Rp186,248,080 Rp279,610,987 Rp279,610,987 [Rp / -]
Total Liabilities Rp112,027,143 Rp147,693,809 Rp147,693,809 [Rp / -]
Total Equity Rp74,220,936 Rp131,917,178 Rp131,917,178 [Rp / -]
Page 12
The impact of the aforementioned Information event on the Company’s operational activities, legal aspects, financial
condition, or business continuity is as follows:
The plan to change the use of proceeds from the Initial Public Offering (IPO) does not have a material impact on the
Company’s operational activities, legal aspects, financial condition, or business continuity.
VI. STATEMENT OF THE BOARD OF DIRECTORS
The Board of Directors of the Company declares that all information in this Information Disclosure has been submitted
completely, accurately, and is not misleading, and that there is no other material information that has not been
disclosed which could cause the information in this Information Disclosure to become inaccurate or misleading.
VII. CLOSING
The Company is committed to continuously complying with the prevailing laws and regulations in the capital market
sector and to upholding the principles of information disclosure to the public. This change in the use of proceeds is
expected to support operational needs, maintain the quality of the production process, and provide sustainable
benefits for the Company and its shareholders.
VIII. ADDITIONAL INFORMATION
Shareholders who require additional information in connection with this event may contact the Company on any business
day during the Company’s business hours at the address set out below:
PT Prodia Diagnostic Line Tbk
Kawasan Industri Jababeka III, Jl. Tekno Boulevard Blok A3 Unit 3A-5-6, West Java 17530, Indonesia
Phone: (021) 21-8984 2722
Email: corporate.secretary@proline.co.id
Website: www.proline.co.id
Cikarang, September 17, 2026
Board of Directors of the Company
Names mentioned 5 people and organisations named in the text · linked when the evidence is strong
unresolved
org
FINANCIAL SERVICES AUTHORITY
p.9 ×3
unresolved
org
Indonesia Stock Exchange
p.11
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.